Neuroscience Gains Traction as AbbVie's Second Growth Pillar, Easing Concentration Risk

What happened

AbbVie's neuroscience segment grew revenue 20% in the latest quarter, prompting management to project $12.7 billion in sales for the year. This marks a shift from the prior narrative that focused almost exclusively on the immunology franchise led by Skyrizi and Rinvoq. While the new figure still represents less than 20% of the company's expected $67 billion total revenue, it introduces a third major revenue source beyond immunology and aesthetics. The deep value master report had not previously highlighted neuroscience as a primary driver, meaning its risk assessment of two-product concentration may need recalibration. However, one quarter of strong growth does not yet establish the durability or competitive positioning of the neuroscience portfolio, and investors should demand more evidence before altering the core thesis.

Implication

AbbVie's neuroscience growth begins to address the key concentration risk that underpinned the cautious stance in the master report. Investors should monitor whether the 20% growth rate is driven by volume, pricing, or one-time factors, and whether management's $12.7 billion projection is achievable. A sustained neuroscience contribution above $10 billion annually would meaningfully diversify revenue and could support a higher valuation multiple over time. However, the segment's competitive dynamics and patent cliffs are not yet well understood, and the company's disclosures on product-level performance remain limited. We would look for at least two more quarters of consistent growth and management's detailed breakdown before revising the thesis or rating upward.

Thesis delta

The prior thesis emphasized concentration risk from Skyrizi and Rinvoq, which together accounted for about 42% of 2025 revenue. The new neuroscience data suggests a third revenue pillar is emerging, potentially reducing that risk. However, the segment's size relative to immunology is still modest, and its durability is unproven, so the overall WAIT rating and entry/trim levels are unchanged pending further confirmation.